Astellas Closing Two U.S. Labs in R&D Restructuring
Astellas said yesterday it will shut down this year two U.S. laboratories obtained in recent acquisitions, narrow the focus of its Astellas Research Institute, and shutter a Japanese lab in 2015, all as part of an R&D restructuring.
AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
AbbVie (NYSE: ABBV) and Alvine Pharmaceuticals, a leader in celiac disease therapeutics development, announced today that they have entered into a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in Phase 2 development
Abbott Gets CE Marking For ARCHITECT Clinical Chemistry Hemoglobin A1c Test
Abbott Laboratories (ABT: Quote) Thursday announced CE Marking for the ARCHITECT clinical chemistry Hemoglobin A1c or HbA1c test, which the firm said may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.
OTHER NEWS & Articles:
What’s behind the FDA’s push for more patient engagement (hint: it’s not that everyone else is doing it) May 13, 2013 11:04 am by Deanna Pogorelc | Lately, the U.S. Food and Drug Administration seems to be doing a bit of re-branding: A new Patient Network site is anchoring a push for more patient engagement in the ..
Myth #1: My existing network will open enough doors to get us funded!
May 14, 2013 7:15 am by Patrick Donohue | Big network? Big deal! The reality is that only one network matters when it comes to raising capital. That network is the group of individuals who are absolutely passionate about …
Big Pharma Is Selling Fewer Pills, But Charging More
May 9, 2013, Matthew Herper, Forbes Staff | As many popular drugs have gone generic, drug makers have seen steep declines in the number of prescription drugs they sell, but it hasn’t hurt revenue as much as one would expect.
U.S. Supreme Court rules for Monsanto in patent fight
May 13 2013, By Lawrence Hurley | In a ruling that drew sighs of relief from the biotechnology industry, the U.S. Supreme Court ruled on Monday that an Indiana farmer violated agribusiness company Monsanto Co.‘s patent for a type of soybean.
AdvaMed 2013 call for company presentations closes May 24th!
Gain maximum visibility for your company at AdvaMed 2013 by presenting to strategic investors and other potential partners who may be the connection you need to achieve your next big milestone.
Do you have news you would like to share? Email me, firstname.lastname@example.org. This is a conversation, not an editorial. Did I forget something, get it wrong or do you agree? Please Comment, Like, Re-Tweet and Share
- U.S. top court backs Monsanto’s patent on genetically modified soybeans (business.financialpost.com)